Managing QT prolongation in the Era of Coronavirus Disease 2019 (COVID-19)

Coronavirus Disease 2019 (COVID-19) has spread around the world and become pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This disease has resulted in significant morbidity and mortality around the world. Reports have shown good clinical outcome with the use of chloroquine and hydroxychloroquine, also combination with addition of azithromycin. These drugs are known to prolong the QT interval, which may increase the risk and incident of Torsade de Pointes (TdP). These risks may be higher in several conditions such as critically ill patients, hospitalized COVID-19 patients with metabolic disorders, multiorgan failure and drug-drug interactions. As cardiologist, we should manage this combination therapy to reduce the risk of TdP.

Abstract licence: CC BY

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.